WO2023037320 - MUCOSAL MESSENGER RNA VACCINE
National phase entry:
Publication Number
WO/2023/037320
Publication Date
16.03.2023
International Application No.
PCT/IB2022/058528
International Filing Date
09.09.2022
Title **
[English]
MUCOSAL MESSENGER RNA VACCINE
[French]
VACCIN À ARN MESSAGER MUQUEUX
Applicants **
INTRON BIOTECHNOLOGY, INC.
Inventors
YOON, Seong Jun
KWON, An Sung
JUN, Soo Youn
PARK, Ji Sung
PARK, Seon Ho
KANG, Sang Hyeon
Priority Data
63/243,086
10.09.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
MOIP
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1954 | |
| EPO | Filing, Examination, Granting | 11587 | |
| Japan | Filing, Examination, Granting | 1991 | |
| South Korea | Filing, Examination, Granting | 1418 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,690
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention is related to a mucosal mRNA vaccine. More specifically, the present invention relates to novel mucosal mRNA vaccine based on a peptide-conjugated, mRNA loaded nanoparticle with enhanced vaccine efficacy, and a method of preparing the same.[French]
La présente invention concerne un vaccin à base d'ARNm muqueux. Plus spécifiquement, la présente invention concerne un nouveau vaccin d'ARNm muqueux basé sur une nanoparticule chargée d'ARNm conjugué à un peptide ayant une efficacité de vaccin améliorée et un procédé de préparation de celui-ci.